WCN25-3862 Exploring the efficacy of Rituximab in treatment-resistant primary FSGS
Primary focal segmental glomerulosclerosis (FSGS) that does not respond to treatment is likely to progress rapidly to end-stage renal disease. [1] There is limited data available on the use of rituximab in cases that do not respond to treatment. This study was conducted to investigate the effectiveness of rituximab in cases of treatment-resistant FSGS.
Authors
- Majibullah Ansari (ORCID: https://orcid.org/0009-0009-2759-7525)
- Abhilash Chandra (ORCID: https://orcid.org/0000-0002-9055-4351)
- Namrata Rao (ORCID: https://orcid.org/0000-0002-5733-4218)
Institutions
- Dr. Ram Manohar Lohia Institute of Medical Sciences (IN)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1016/j.ekir.2024.11.1037
- Primary Topic
- Urticaria and Related Conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00